Skip to main content

Advertisement

SpringerLink
Log in

Increase in ezrin expression from benign to malignant breast tumours

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Purpose

Ezrin is known to be involved in intercellular interactions, and a shift from membrane-bound to cytoplasmatic protein expression has been associated with malignant potential. This association has primarily been demonstrated in cell lines and, as yet, little is known about the distribution of ezrin in primary benign and malignant breast tissues. We have, therefore, set out to investigate ezrin protein expression in a series of primary breast lesions.

Methods

Immunohistochemistry was used to detect ezrin expression in 465 samples of normal breast tissues, benign breast tumours, pre-invasive breast lesions, breast cancer tissues and metastatic lymph nodes, and the protein expression patterns observed were correlated with clinicopathological parameters.

Results

Ezrin was detected in the cytoplasm of both benign and malignant breast tissues, but its expression was significantly higher in the malignant tissues (13 % vs 60 %, p < 0.0001; χ 2 test). We also detected a statistically significant higher ezrin expression in pre-invasive lesions compared to benign lesions (15 % vs 44 %, p = 0.04; χ 2 test). We did not find such a difference in ezrin expression between pre-invasive and invasive cancer samples, nor between invasive cancer samples and lymph node metastases. Within the group of invasive cancer samples, we found a significant correlation between ezrin expression and CK14 (rs:0.38, p < 0.007) and Her2 (rs:0.25, p < 0.002) expression. No such correlation was observed between ezrin expression and nodal status, grading, patient’s age, hormone receptor status, and Ki67 or p53 expression.

Conclusion

Taken together, we found that cytoplasmatic ezrin expression increases from benign to malignant breast tumour development. We hypothesize that the tissue architectural alterations that are associated with aberrant ezrin expression may point at pathophysiological mechanisms that may be instrumental for the design of novel therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. K.A. Swanson, D.D. Crane, H.D. Caldwell, Chlamydia trachomatis species-specific induction of ezrin tyrosine phosphorylation functions in pathogen entry. Infect. Immun. 75, 5669–5677 (2007)

    Article  PubMed  CAS  Google Scholar 

  2. A. Fadiel, H.H. Lee, N. Demir, S. Richman, A. Iwasaki, K. Connell, F. Naftolin, Ezrin is a key element in the human vagina. Maturitas 60, 31–41 (2008)

    Article  PubMed  CAS  Google Scholar 

  3. A. Bretscher, Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr. Opin. Cell Biol. 11, 109–116 (1999)

    Article  PubMed  CAS  Google Scholar 

  4. S. Tsukita, S. Yonemura, S. Tsukita, ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr. Opin. Cell Biol. 9, 70–75 (1997)

    Article  PubMed  CAS  Google Scholar 

  5. S. Fais, A role for ezrin in a neglected metastatic tumor function. Trends Mol. Med. 10, 249–250 (2004)

    Article  PubMed  CAS  Google Scholar 

  6. S. Tsukita, K. Oishi, N. Sato, J. Sagara, A. Kawai, S. Tsukita, ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 126, 391–401 (1994)

    Article  PubMed  CAS  Google Scholar 

  7. S. Yonemura, M. Hirao, Y. Doi, N. Takahashi, T. Kondo, S. Tsukita, S. Tsukita, Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J. Cell Biol. 140, 885–895 (1998)

    Article  PubMed  CAS  Google Scholar 

  8. M. Curto, A.I. McClatchey, Ezrin…a metastatic detERMinant? Cancer Cell 5, 113–114 (2004)

    Article  PubMed  CAS  Google Scholar 

  9. D.T. Dransfield, A.J. Bradford, J. Smith, M. Martin, C. Roy, P.H. Mangeat, J.R. Goldenring, Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 16, 35–43 (1997)

    Article  PubMed  CAS  Google Scholar 

  10. K.W. Hunter, Ezrin, a key component in tumor metastasis. Trends Mol. Med. 10, 201–204 (2004)

    Article  PubMed  CAS  Google Scholar 

  11. X. Yao, L. Cheng, J.G. Forte, Biochemical characterization of ezrin-actin interaction. J. Biol. Chem. 271, 7224–7229 (1996)

    Article  PubMed  CAS  Google Scholar 

  12. P. Pujuguet, L. Del Maestro, A. Gautreau, D. Louvard, M. Arpin, Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol. Biol. Cell 14, 2181–2191 (2003)

    Article  PubMed  CAS  Google Scholar 

  13. M. Berryman, Z. Franck, A. Bretscher, Ezrin is concentrated in the apical microvilli of a wide variety of eptihelial cells whereas moesin is found primarily in endothelial cells. J. Cell Sci. 105, 1025–1043 (1993)

    PubMed  CAS  Google Scholar 

  14. A. Gautreau, P. Poullet, D. Louvard, M. Arpin, Ezrin, a plasma memrane- microfilament linker, signals cell survival through the phosphatidylinositol 3- kinase/Akt pahtway. Proc. Natl. Acad. Sci. U. S. A. 96, 7300–7305 (1999)

    Article  PubMed  CAS  Google Scholar 

  15. A.I. McClatchey, Merlin and ERM proteins: unappreciated roles in cancer development? Nat. Rev. Cancer 3, 877–883 (2003)

    Article  PubMed  Google Scholar 

  16. B. Bruce, G. Khanna, L. Ren, G. Landberg, K. Jirström, C. Powell, A. Borczuk, E.T. Keller, K.J. Wojno, P. Meltzer, K. Baird, A. McClatchey, A. Bretscher, S.M. Hewitt, C. Khanna, Expression of the cytoskeleton linker protein ezrin in human cancers. Clin. Exp. Metastasis 24, 69–78 (2007)

    Article  PubMed  CAS  Google Scholar 

  17. T.A. Martin, G. Harriso, R.E. Mansel, W.G. Jiang, The role of the CD44/ezrin complex in cancer metastasis. Crit. Rev. Oncol. Hematol. 46, 165–186 (2003)

    Article  PubMed  Google Scholar 

  18. A. Gautreau, D. Louvard, M. Arpin, ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr. Opin. Cell Biol. 14, 104–109 (2002)

    Article  PubMed  CAS  Google Scholar 

  19. N. Koon, R. Schneider-Stock, M. Sarlomo-Rikala, J. Lasota, M. Smolkin, G. Petroni, A. Zaika, C. Boltze, F. Meyer, L. Andersson, S. Knuutila, M. Miettinen, W. El-Rifai, Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53, 235–240 (2004)

    Article  PubMed  CAS  Google Scholar 

  20. S.C. Kaul, Y. Mitsui, Y. Komatsu, R.R. Reddel, R. Wadhwa, A highly expressed 81kDa protein in immortalized mouse fibroblast: its proliferative function and identity with ezrin. Oncogene 13, 1231–1237 (1996)

    PubMed  CAS  Google Scholar 

  21. Z.Y. Shen, L.Y. Xu, M.H. Chen, E.M. Li, J.T. Li, X.Y. Wu, Y. Zeng, Upregulated expression of Ezrin and invasive phenotype in malignantly transformed esophageal epithelial cells. World J. Gastroenterol. 9, 1182–1186 (2003)

    PubMed  CAS  Google Scholar 

  22. K. Ohtani, H. Sakamoto, T. Rutherford, Z. Chen, K. Satoh, F. Naftolin, Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett. 147, 31–38 (1999)

    Article  PubMed  CAS  Google Scholar 

  23. C. Khanna, J. Khan, P. Nguyen, J. Prehn, J. Caylor, C. Yeung, J. Trepel, P. Meltzer, L. Helman, Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 61, 3750–3759 (2001)

    PubMed  CAS  Google Scholar 

  24. C. Khanna, X. Wan, S. Bose, R. Cassaday, O. Olomu, A. Mendoza, C. Yeung, R. Gorlic, S.M. Hewitt, L.J. Helman, The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10, 182–186 (2004)

    Article  PubMed  CAS  Google Scholar 

  25. S. Ferrari, L. Zanella, M. Alberghini, E. Palmerini, E. Staals, P. Bacchini, Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr. Blood Cancer 50, 752–756 (2008)

    Article  PubMed  Google Scholar 

  26. Y. Yu, J. Khan, C. Khanna, L. Helman, P.S. Meltzer, G. Merlino, Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat. Med. 10, 175–181 (2004)

    Article  PubMed  CAS  Google Scholar 

  27. N. Akisawa, I. Nishimori, T. Iwamura, S. Onishi, M.A. Hollingsworth, High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem. Biophys. Res. Commun. 258, 395–400 (1999)

    Article  PubMed  CAS  Google Scholar 

  28. H.J. Wang, J.S. Zhu, Q. Zhang, Q. Sun, H. Guo, High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J. Gastroenterol. 15, 2016–2019 (2009)

    Article  PubMed  CAS  Google Scholar 

  29. J. Musiał, S. Sporny, A. Nowicki, Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. Pol. J. Pathol. 58, 235–243 (2007)

    PubMed  Google Scholar 

  30. S.T. Pang, X. Fang, A. Valdman, G. Norstedt, A. Pousette, L. Egevad, P. Ekman, Expression of ezrin in prostatic intraepithelial neoplasia. Urology 63, 609–612 (2004)

    Article  PubMed  Google Scholar 

  31. Z. Chen, A. Fadiel, Y. Feng, K. Ohtani, T. Rutherford, F. Naftolin, Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer 92, 3068–3075 (2001)

    Article  PubMed  CAS  Google Scholar 

  32. K. Ohtani, H. Sakamoto, T. Rutherford, Z. Chen, A. Kikuchi, T. Yamamoto, K. Satoh, F. Naftolin, Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett. 179, 79–86 (2002)

    Article  PubMed  CAS  Google Scholar 

  33. B.E. Elliott, J.A. Meens, S.K. SenGupta, D. Louvard, M. Arpin, The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 7, R365–R373 (2005)

    Article  PubMed  CAS  Google Scholar 

  34. Q. Li, M. Wu, H. Wang, G. Xu, T. Zhu, Y. Zhang, P. Liu, A. Song, C. Gang, Z. Han, J. Zhou, L. Meng, Y. Lu, S. Wang, D. Ma, Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett. 261, 55–63 (2008)

    Article  PubMed  CAS  Google Scholar 

  35. E.D. Coene, C. Gadelha, N. White, A. Malhas, B. Thomas, M. Shaw, D.J. Vaux, A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J. Cell Biol. 192, 497–512 (2011)

    Article  PubMed  CAS  Google Scholar 

  36. D. Sarrio, S.M. Rodriguez-Pinilla, A. Dotor, F. Calero, D. Hardisson, J. Palacios, Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res. Treat. 98, 71–79 (2006)

    Article  PubMed  CAS  Google Scholar 

  37. A. Halon, P. Donizy, P. Surowiak, R. Matkowski, ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up. Cell. Oncol. (2013, Feb 19).

  38. A.A. Arslan, D. Silvera, R. Arju, S. Giashuddin, I. Belitskaya-Levy, S.C. Formenti, R.J. Schneider, Atypical ezrin localization as a marker of locally advanced breast cancer. Breast Cancer Res. Treat. 134, 981–988 (2012)

    Article  PubMed  CAS  Google Scholar 

  39. J. Moilanen, H. Lassus, A. Leminen, A. Vaheri, R. Butzow, O. Carpen, Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol. Oncol. 90, 273–281 (2003)

    Article  PubMed  CAS  Google Scholar 

  40. K.D. Geiger, P. Stoldt, W. Schlote, A. Derouiche, Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am. J. Pathol. 157, 1785–1793 (2000)

    Article  PubMed  CAS  Google Scholar 

  41. S. Ilmonen, A. Vaheri, S. Asko-Seljavaara, O. Carpen, Ezrin in primary cutaneous melanoma. Mod. Pathol. 2, 1–8 (2004)

    Google Scholar 

  42. S. Zheng, J. Huang, K. Zhou, C. Zhang, Q. Xiang, Z. Tan, T. Wang, X. Fu, 17β-estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS ONE 6, e22439 (2011)

    Article  PubMed  CAS  Google Scholar 

  43. L. Ma, X.H. Zhang, L.X. Xing, Y.H. Li, X.L. Wang, Y.J. Wang, Relationship of ezrin protein expression to the carcinogenesis and prognosis of infiltrating breast ductal carcinoma. Zhonghua Zhong Liu Za Zhi 30, 279–283 (2008)

    PubMed  CAS  Google Scholar 

  44. F. Rastelli, S. Biancanelli, A. Falzetta, A. Martignetti, C. Casi, R. Bascioni, L. Giustini, S. Crispino, Triple- negative breast cancer: current state of the art. Tumori 96, 875–888 (2010)

    PubMed  Google Scholar 

  45. Q. Li, M.F. Wu, A.P. Song, J.C. Wei, G. Xu, Y.P. Lu, D. Ma, Expression of ezrin and e-cadherin in invasive ductal breast cancer and their correlations to lymphatic metastasis. Ai Zheng 25, 363–366 (2006)

    PubMed  CAS  Google Scholar 

  46. L. Ma, Y.P. Liu, X.H. Zhang, C.Z. Geng, Z.H. Li, Relationship of RhoA signaling activity with ezrin expression and ist significance in the prognosis for breast cancer patients. Chin. Med. J. 126, 242–247 (2013)

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of OB/GYN, Division of General Gynecology and Gynecologial Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Daphne Gschwantler-Kaulich, Camilla Natter & Christian F. Singer

  2. Department of Pathology, University Hospital Hamburg Eppendorf, Hamburg, Germany

    Stefan Steurer

  3. Institute of Anatomy, Histology, and Embryology, University of Veterinary Medicine, Vienna, Austria

    Ingrid Walter

  4. University of Klagenfurt, Klagenfurt, Austria

    Almut Thomas

  5. Department of Thoracic Surgery, Otto Wagner Spital, Vienna, Austria

    Mohamed Salama

Authors
  1. Daphne Gschwantler-Kaulich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camilla Natter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Steurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ingrid Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Almut Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamed Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian F. Singer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daphne Gschwantler-Kaulich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gschwantler-Kaulich, D., Natter, C., Steurer, S. et al. Increase in ezrin expression from benign to malignant breast tumours. Cell Oncol. 36, 485–491 (2013). https://doi.org/10.1007/s13402-013-0153-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-013-0153-5

Keywords

Search

Navigation